February 2008
Pharmaceutical Representative;Feb2008, Vol. 38 Issue 2, p11
The article presents a randomized and double-blind study which revealed that Allergan's Lumigan (bimatoprost), a prostamide, can lower the intraocular pressure in the U.S. The participants of the study are 200 patients with glaucoma or ocular hypertension treated with a non-fixed combination of latanoprost and timolol. The study found that daytime intraocular pressure increased by 0.3 millimeter of mercury (mm Hg) for the bimatoprost arm and nighttime pressure decreased by 0.8 mm Hg.


Related Articles

  • Introduction. Realini, Tony; Fechtner, Robert D. // Ophthalmology Times;8/1/2013 Supplement, p3 

    An introduction to the transcript of a roundtable discussion on lowering intraocular pressure (IOP), which featured a panel of glaucoma specialists, is presented.

  • Glaucoma Drugs Show Similar Additive Efficacy.  // Review of Ophthalmology;Aug2010, Vol. 17 Issue 8, p79 

    The article offers updates concerning ophthalmology research in the U.S. A study shows that alpha adrenergic agonists, beta adrenergic antagonists, and carbonic anhydrase inhibitors combined with a prostaglandin analog lower the mean diurnal intraocular pressure. A study in Dallas, Texas found...

  • Changes in Trend of Newly Prescribed Anti-Glaucoma Medications in Recent Nine Years in a Japanese Local Community. Kashiwagi, Kenji // Open Ophthalmology Journal;2010, p7 

    Purpose: To investigate changes in the trend of anti-glaucoma ophthalmic solutions in 2000-2008 in a Japanese local community. Materials and Methods: The subjects of this study were patients with glaucoma who were registered in the database of the glaucoma clinic of University of Yamanashi...

  • PRIMARY CHRONIC ANGLE CLOSURE GLAUCOMA.  // Review of Optometry;4/15/2010 Supplement, p33A 

    The article focuses on primary chronic angle closure glaucoma (PCACG). It highlights the signs and symptoms of PCACG which commonly affected women and patients of Asian descent. It cites medical therapy that is effective in ameliorating the intraocular pressure (OIP) in eyes with PCACG including...

  • Systemic beta-blockers, nitrates may be independently linked with lower IOP. Kronemyer, Bob // Ocular Surgery News;10/10/2014, Vol. 32 Issue 19, p28 

    The article focuses on the study published in "Ophthalmology" which revealed that the use of systemic beta-blockers or nitrates may reduce intra-ocular pressure (IOP). The potential of statins and aspirin in lowering the IOP is also highlighted. Issues addressed by ophthalmologist Anthony P....

  • Will New Approvals Put Prostaglandins Over the Top?  // Review of Ophthalmology;Apr2001, Vol. 8 Issue 4, p4 

    Discusses the possibility of prostaglandins becoming the favored drug over beta-blockers among opthalmologists for glaucoma therapy. Approval by the Food and Drug Administration of both Allergan's Lumigan and Alcon's Travatan; Patients' responses to the different drugs used in Phase III...

  • Possibilities for first-line glaucoma therapy expanding. Yashar, Alyson G.; Katz, L. Jay; Higginbotham, Eve; Camras, Carl; Cantor, Louis // Ophthalmology Times;04/15/99, Vol. 24 Issue 8, p38 

    Provides information on the discussion on which agents are best as first-line glaucoma therapy at the Glaucoma Symposium of the American Academy of Ophthalmology. Types of beta-blockers use for the treatment of glaucoma; Purpose of using alpha-agonists; Dosage of prostaglandin given for the...

  • How best to take on glaucoma therapy. Diamond, Jeremy // GP: General Practitioner;6/17/2002, p73 

    Studies the use of prostaglandin analogs latanoprost and travoprost in treating glaucoma. Comparison on the effectiveness of the analogs with beta-blockers; Ocular side effects associated with the analogs; Need for latanoprost to be refrigerated before opening.

  • The Management of Glaucoma. Fingerel, Murray // Review of Optometry;9/15/2009 Part 2 of 2, Vol. 146 Issue 9, p15 

    The article discusses the management of glaucoma. It notes the situations that confront the optometrist whether to initiate therapy for glaucoma such as when optic nerve and/or visual field damage is detected. It mentions the identification of intraocular pressure (IOP) range before the start of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics